share_log

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case

Seagen Wins $42M Patent Claim Against Daiichi In Cancer Drug Case

SeaGen在抗癌藥物案中贏得對Daiichi的4200萬美元專利索賠
Benzinga Real-time News ·  2022/04/11 09:20

A jury in Marshall, Texas, awarded Seagen Inc (NASDAQ:SGEN) $41.82 million from Daiichi Sankyo Co (OTC:DSNKY) over claims that Daiichi and AstraZeneca plc's (NASDAQ:AZN) breast-cancer drug Enhertu violates Seagen's patent rights.

得克薩斯州馬歇爾的陪審團裁定SeaGen公司(納斯達克：SGEN)4,182萬美元第一三共公司(場外交易：DSNKY)就Daiichi和阿斯利康納斯達克(Sequoia Capital：AZN)治療乳腺癌的藥物恩海圖侵犯了西根公司的專利權。

  • The jury found that Daiichi willfully infringed a patent owned by Seagen that covers technology for delivering chemotherapy drugs to cancer cells.
  • Naoto Tsukaguchi, Corporate Officer and General Counsel, Daiichi Sankyo, said in a statement, "Daiichi Sankyo disagrees with the jury verdict, is committed to defending its rights, and will explore options with respect to the jury verdict, including post-trial motions and an appeal."
  • Seagen said it was pleased with the verdict and would request additional royalties on future sales of Enhertu in the U.S. until the patent expires in November 2024.
  • Seagen filed the lawsuit in the U.S. District Court for the Eastern District of Texas in 2020, claiming Enhertu works in the same way as its patent related to antibody-drug conjugates, which use antibodies to target cancer cells with chemotherapy drugs.
  • Price Action: SGEN shares closed 2.74% lower at $151.84 on Friday.
  • 陪審團發現，Daiichi故意侵犯了Seagen擁有的一項專利，該專利涵蓋了將化療藥物輸送到癌細胞的技術。
  • 三共株式會社社長兼法律總顧問津口直人在一份聲明中表示：“三共不同意陪審團的裁決，致力於捍衞自己的權利，並將探索有關陪審團裁決的選擇，包括庭審後動議和上訴。”
  • SeaGen表示，它對這一判決感到高興，並將要求對Enhertu未來在美國的銷售收取額外的版税，直到該專利於2024年11月到期。
  • SeaGen於2020年向美國德克薩斯州東區地區法院提起訴訟，聲稱Enhertu的工作原理與其與抗體-藥物結合物相關的專利相同，後者使用抗體通過化療藥物靶向癌細胞。
  • 價格行動：Sgen股價週五收低2.74%，報151.84美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論